Mind Cure Health, a Vancouver, British Columbia-based mental health firm, announced this week that it has signed a letter of intent to acquire an ownership interest in ATMA Journey Centers, a Calgary, Alberta-based treatment center that provides psychedelic-assisted therapy for patients who qualify under Canada’s Section 56 exemption.
The partnership will allow for researchers and therapists to participate in Mind Cure research programs that are focused on pain, neurogeneration, migraines and cluster headaches. It will also facilitate syndication of Mind Cure’s psychedelic drug protocols and use of its iSTRYM digital therapeutics platform, which was unveiled last week.
The deal with ATMA is the latest in a series of recent moves for Mind Cure:
- In November, the organization named Ryan Hartwell, PhD, as its chief science officer, and in early December, promoted chief operating officer Kelsey Ramsden to the role of president and CEO.
- Later in December, Mind Cure announced a translational research program that will initially focus on psilocybin, ketamine and ibogaine for use in pharmaceuticals to treat physical and psychological pain, as well as related mental health illnesses.
- On Dec. 10, Mind Cure unveiled plans to open its first Mind Cure Health Center in British Columbia, which will offer psychedelic-assisted mental health therapy and training for therapists, with access to ketamine and psilocybin, beginning in May.